Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCis, a drug research and development company, has started Phase I clinical testing of ProtoCure intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by the company, which effectively prevents cancer growth and proliferation locally.
Subscribe to our email newsletter
The open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of the locally administered product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer, and is expected to be well tolerated.
Lasse Leino, CEO, BioCis Pharma, said: We are pleased to advance to clinical testing with the ProtoCure instillation solution.
“The ProtoCure cancer drug holds great promise for patients suffering from superficial bladder cancer. We are committed to take the product quickly to more extensive clinical efficacy testing after this preliminary safety study. We expect to get results from this study by the first quarter of 2010, he added.